 Pre-Exposure Prophylaxis
"Pre-Exposure Prophylaxis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of disease prevention (abbreviated PrEP) which involves the administration of drugs to at-risk persons who have not been exposed to the disease-causing agent.
| Descriptor ID |
D065129
|
| MeSH Number(s) |
N02.421.726.758.655 N06.850.780.680.655
|
| Concept/Terms |
Pre-Exposure Prophylaxis- Pre-Exposure Prophylaxis
- Pre Exposure Prophylaxis
- Pre-Exposure Prophylaxi
- Prophylaxi, Pre-Exposure
- Prophylaxis, Pre-Exposure
- Pre-Exposure Prophylaxis (PrEP)
- Pre Exposure Prophylaxis (PrEP)
- Pre-Exposure Prophylaxi (PrEP)
- Prophylaxi, Pre-Exposure (PrEP)
- Prophylaxis, Pre-Exposure (PrEP)
|
Below are MeSH descriptors whose meaning is more general than "Pre-Exposure Prophylaxis".
Below are MeSH descriptors whose meaning is more specific than "Pre-Exposure Prophylaxis".
This graph shows the total number of publications written about "Pre-Exposure Prophylaxis" by people in this website by year, and whether "Pre-Exposure Prophylaxis" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 3 | 1 | 4 | | 2015 | 4 | 2 | 6 | | 2016 | 9 | 0 | 9 | | 2017 | 13 | 2 | 15 | | 2018 | 16 | 5 | 21 | | 2019 | 11 | 5 | 16 | | 2020 | 10 | 4 | 14 | | 2021 | 28 | 2 | 30 | | 2022 | 18 | 0 | 18 | | 2023 | 15 | 0 | 15 | | 2024 | 16 | 1 | 17 | | 2025 | 9 | 1 | 10 |
To return to the timeline, click here.
Below are the most recent publications written about "Pre-Exposure Prophylaxis" by people in Profiles.
-
Engel N, Sykes C, Schauer AP, Kashuba ADM, Anderson PL, Bushman LR, Cottrell ML. Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application. J Antimicrob Chemother. 2025 Oct 03; 80(10):2727-2731.
-
Anderson PL, Coppinger C, Cottrell ML, Marzinke MA. Recommendations for Interpreting Intraerythrocytic Tenofovir Diphosphate and Emtricitabine Triphosphate for HIV-1 Preexposure Prophylaxis Adherence Assessment. J Acquir Immune Defic Syndr. 2025 Oct 01; 100(2):162-169.
-
Mugwanya KK, Saina M, Mugo NR, MaWhinney S, Morrow M, Schaafsma TT, Donnell D, Glidden DV, Ngure K, Brown CE, Rechkina EA, Chohan BH, Wu L, Hill E, Koome E, Akelo N, Mbaire S, Morrison SA, Kibatha M, Njeru I, Muriithi M, Coppinger C, Bushman L, Baeten JM, Anderson PL. Adherence thresholds for emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis against HIV acquisition in cisgender women: A randomized directly observed dosing study. PLoS Med. 2025 Sep; 22(9):e1004732.
-
Parikh UM, Kudrick LD, Levy L, Bosek E, Chohan BH, Mukui I, Masyuko S, Ndlovu N, Mahaka I, Mugurungi O, Ncube G, Hettema A, Matse SN, Mullick S, Wallis CL, Heaps AL, Penrose KJ, McCormick KD, Wiesner L, Anderson PL, Peterson JM, Celum C, Richardson BA, Castor D, Allen S, Torjesen K, Mellors JW. A cross-sectional study evaluating the frequency of HIV drug resistance mutations among individuals diagnosed with HIV-1 in tenofovir disoproxil fumarate-based pre-exposure prophylaxis rollout programmes in Kenya, Zimbabwe, Eswatini and South Africa. J Int AIDS Soc. 2025 Aug; 28(8):e70011.
-
Meyers K, Lane B, Zucker J, Wu Y, Carnevale C, Burnside H, Rowan S, Mayes E, Narcisse-Cempini G, Gold MA, Saldana L, Golub SA. A case study of the co-creation of the PrEP-SIC: a roadmap to support introduction of pre-exposure prophylaxis into new settings. BMC Health Serv Res. 2025 May 01; 25(1):631.
-
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. No significant drug-drug interaction between oral TAF-based PrEP and feminizing hormone therapy among transgender women in Thailand: the iFACT-3 study. J Int AIDS Soc. 2025 May; 28(5):e26502.
-
Elbur AI, Donnell D, Hosek S, Dye B, Velloza J, Delany-Moretlwe S, Celum C. The Association Between Use of Adherence Support Interventions and Adherence to HIV Preexposure Prophylaxis Among Young South African and Zimbabwean Women in HPTN 082. AIDS Behav. 2025 Aug; 29(8):2483-2494.
-
Hiransuthikul A, Thammajaruk N, Kerr S, Janamnuaysook R, Nonenoy S, Hongchookiat P, Trichavaroj R, Tawon Y, Boonruang J, Teeratakulpisarn N, Cressey TR, Anderson PL, Phanuphak N. Exploring potential drug-drug interactions between masculinizing hormone therapy and oral pre-exposure prophylaxis (F/TDF and F/TAF) among transgender men (iMACT study): a randomized, open-label pharmacokinetic study in Thailand. J Int AIDS Soc. 2025 Apr; 28(4):e26445.
-
Noguchi LM, Owor M, Mgodi NM, Gati Mirembe B, Dadabhai S, Horne E, Gundacker H, Richardson BA, Bunge K, Scheckter R, Song M, Marzinke MA, Anderson PL, Livant E, Jacobson C, Piper JM, Chakhtoura N, Hillier SL, Balkus JE. Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trial. Lancet HIV. 2025 Mar; 12(3):e180-e190.
-
McGarrity MW, MacPherson P, Li A, Naccarato M, Anderson P, Tan DHS. Intracellular tenofovir-diphosphate concentrations in HIV pre-exposure prophylaxis users who underwent bariatric surgery. HIV Med. 2025 Apr; 26(4):643-649.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|